期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 17, 页码 12572-12581出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00395
关键词
-
资金
- Wntrix Inc.
- Cancer Prevention and Research Institute of Texas [RP190542]
- Janice David Gordon for Bowel Cancer Research Endowment
- National Cancer Institute [R01CA226894]
LGR4-6 are related receptors commonly upregulated in gastrointestinal cancers, with LGR5 being enriched in cancer stem cells. Targeting all three LGRs simultaneously is proposed for a more effective anti-tumor approach. A drug conjugate comprising an RSPO4 mutant and IgG1-Fc showed potent cytotoxic effects on cancer cells expressing any LGR, suppressing tumor growth without adverse effects.
LGR4-6 (leucine-rich repeat-containing G-protein-coupled receptors 4, 5, and 6) are three related receptors with an upregulated expression in gastrointestinal cancers to various extents, and LGR5 is enriched in cancer stem cells. Antibody-drug conjugates (ADCs) targeting LGR5 showed a robust antitumor effect in vivo but could not eradicate tumors due to plasticity of LGR5-positive cancer cells. As LGR5-negative cancer cells often express LGR4 or LGR6 or both, we reasoned that simultaneous targeting of all three LGRs may provide a more effective approach. R-spondins (RSPOs) bind to LGR4-6 with high affinity and potentiate Wnt signaling. We identified an RSPO4 furin domain mutant (Q65R) that retains potent LGR binding but no longer potentiates Wnt signaling. Drug conjugates of a peptibody comprising the RSPO4 mutant and IgG1-Fc showed potent cytotoxic effects on cancer cell lines expressing any LGR in vitro and suppressed tumor growth in vivo without inducing intestinal enlargement or other adverse effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据